MARKET

ARQT

ARQT

Arcutis Biotherapeutics, Inc.
NASDAQ
31.16
+1.20
+4.01%
After Hours: 31.10 -0.06 -0.19% 19:32 12/04 EST
OPEN
29.37
PREV CLOSE
29.96
HIGH
31.39
LOW
29.37
VOLUME
2.04M
TURNOVER
--
52 WEEK HIGH
31.39
52 WEEK LOW
11.13
MARKET CAP
3.82B
P/E (TTM)
-87.9233
1D
5D
1M
3M
1Y
5Y
1D
Has Arcutis’ 106% 2025 Surge Outrun Its DCF Value and Sales Multiple?
Simply Wall St · 1d ago
Arcutis Biotherapeutics SVP General Counsel Masaru Matsuda Reports Disposal of Common Shares
Reuters · 1d ago
Director Howard G. Welgus Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares
Reuters · 1d ago
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
NASDAQ · 1d ago
Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year?
NASDAQ · 1d ago
Arcutis Biotherapeutics: Behind The Big Rally
Seeking Alpha · 2d ago
MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study
NASDAQ · 2d ago
Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock?
NASDAQ · 2d ago
More
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.

Webull offers Arcutis Biotherapeutics Inc stock information, including NASDAQ: ARQT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARQT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARQT stock methods without spending real money on the virtual paper trading platform.